Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnP Combined With SHR-1701 and Apatinib in First-Line Advanced/Metastatic Pancreatic Cancer
NCT07802184Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, Rivoceranib in pancreatic ductal adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfaRivoceranib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07802184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802184.